期刊
FUTURE MEDICINAL CHEMISTRY
卷 3, 期 11, 页码 1427-1454出版社
FUTURE SCI LTD
DOI: 10.4155/FMC.11.90
关键词
-
资金
- Bill and Melinda Gates Foundation
- Wellcome Trust through the Grand Challenges in Global Health Initiative
- NIH National Institute of Allergy and Infectious Diseases
Tuberculosis remains a leading cause of death resulting from an infectious agent, and the spread of multi-and extensively drug-resistant strains of Mycobacterium tuberculosis poses a threat to management of global health. New drugs that effectively shorten the duration of treatment and are active against drug-resistant strains of this pathogen are urgently required to develop effective chemotherapies to combat this disease. Two nitroimidazoles, PA-824 and OPC-67683, are currently in Phase II clinical trials for the treatment of TB and the outcome of these may determine the future directions of drug development for anti-tubercular nitroimidazoles. In this review we summarize the development of these nitroimidazoles and alternative analogs in these series that may offer attractive alternatives to PA-824 and OPC-67683 for further development in the drug-discovery pipeline. Lastly, the potential pitfalls in the development of nitroimidazoles as drugs for TB are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据